mTORC1 and mTORC2 in cancer and the tumor microenvironment

Area of Science:

• Cellular signaling pathways
• Cancer biology
• Molecular medicine

Background:

• The mammalian target of rapamycin (mTOR) is a central regulator of cell survival, proliferation, and metabolism.
• mTOR functions via two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
• Dysregulation of mTOR signaling is implicated in various diseases, including cancer, diabetes, and neurodegeneration.

Purpose of the Study:

• To review recent advances in understanding the distinct roles of mTORC1 and mTORC2 in cancer.
• To explore the involvement of mTOR signaling in tumor vasculature and immunity.
• To provide an update on mTOR inhibitors for cancer therapy.

Main Methods:

• Literature review of recent research on mTOR signaling in cancer.
• Analysis of genetic alterations in mTORC2-specific genes in human cancers.
• Synthesis of data on mTORC1 and mTORC2 functions in oncogenesis.

Main Results:

• While mTORC1 is well-studied in cancer, emerging evidence highlights mTORC2's distinct role, with some cancers showing mTORC2-specific gene amplifications.
• mTORC2 contributes to cancer progression through mechanisms beyond those of mTORC1.
• mTOR signaling impacts tumor angiogenesis and immune surveillance.

Conclusions:

• Both mTORC1 and mTORC2 play critical roles in cancer development and progression.
• Targeting mTORC2 may offer novel therapeutic strategies for specific cancer types.
• Further research is needed to fully elucidate the differential roles and therapeutic potential of mTORC1 and mTORC2 inhibitors.